PF-07934040 (panKRAS) | Project advanced
Solid Tumors
RAS/KRAS
PF-08046044 (35C) | Project advanced
Advanced Malignancies
CD30-directed antibody TOPO1 drug conjugate
sigvotatug vedotin (PF-08046047) | New project
Advanced Solid Tumors (Biologic)
Integrin beta-6-directed antibody-drug conjugate
vepdegestrant (ARV-471) + CDK4 (PF-07220060) | New project
ER+/HER2- 1L Metastatic Breast Cancer
CDK4 kinase inhibitor + ER-targeting PROTAC protein degrader
PF-07820435 | New project
Solid Tumors
STING agonist
PF-08046045 (SGN-35T) | New project
Advanced Solid Tumors and Lymphomas (Biologic)
CD-30 directed antibody-tripeptide MMAE conjugate
PF-08046050 (SGN-CEACAM5C) | New project
Advanced Solid Tumors (Biologic)
CEACAM5-directed antibody-drug conjugate
PF-08046040 (SEA-CD70) | New project
Myelodysplastic Syndrome and Acute Myeloid Leukemia (Biologic)
Non-fucosylated CD70-directed antibody
PF-08046054 (SGN-PDL1V) | New project
Advanced Solid Tumors (Biologic)
PD-L1-directed antibody-drug conjugate
PF-08046052 (SGN-EGFRd2) | New project
Advanced Solid Tumors (Biologic)
EGFR-targeted bispecific gamma delta T-cell engager
felmetatug vedotin (PF-08046048) (SGN-B7H4V) | New project
Advanced Solid Tumors (Biologic)
B7H4-directed antibody-drug conjugate
PF-08046049 (SGN-BB228) | New project
Advanced Melanoma and Other Solid Tumors (Biologic)
CD228-directed antibody-Anticalin bispecific protein
TIVDAK (tisotumab vedotin) | New project
Recurrent or Metastatic Cervical Cancer (Biologic)
Tissue Factor-directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-06940434 | New project
Solid Tumors (Biologic)
Integrin alpha-V/beta-8 antagonist
atirmociclib (PF-07220060) | New project
1L Metastatic Breast Cancer
CDK4 inhibitor
TUKYSA (tucatinib) | New project
HER2+ Gastrointestinal Cancers (SGNTUC-024)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | New project
Urothelial Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate
PF-07248144 + PF-07220060 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier + CDK4 inh
PF-07799544 | New project
Solid Tumors
MEK brain penetrant inhibitor
PF-07220060 + enzalutamide | New project
Prostate Cancer
CDK4 inhibitor + androgen receptor inhibitor
PF-07104091 | New project
Ovarian Cancer
CDK2 inhibitor
PF-07799933 | New project
Solid Tumors
BRAF Class 1 and Class 2 inhibitor
PF-07104091 + PF-07220060 | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
PF-07284892 | New project
Solid Tumors
SHP2 tyrosine phosphatase inhibitor
PF-07248144 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier
PF-07104091 | New project
Breast Cancer Metastatic
CDK2 inhibitor
atirmociclib (PF-07220060) | Project advanced
Early Breast Cancer
CDK4 inhibitor
Disitamab vedotin (DV) | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
Disitamab vedotin (DV) | New project
2L+ Urothelial Cancer with HER2 Expression (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
Locally Advanced or Metastatic Solid Tumors with HER2 Alterations
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L+ HER2+ mBC (HER2CLIMB-04)
HER2 tyrosine kinase inhibitor
TIVDAK (tisotumab vedotin) | New project
Advanced Solid Tumors (Biologic)
Tissue Factor-directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
Locally Advanced or Metastatic Solid Tumors (Biologic)
Nectin-4 directed antibody-drug conjugate
mevrometostat (PF-06821497) + enzalutamide | New project
Prostate Cancer
EZH2 inhibitor + androgen receptor inhibitor
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa fusion protein
vepdegestrant (ARV-471) | New project
ER+/HER2- Early Breast Cancer
ER-targeting PROTAC protein degrader
atirmociclib (PF-07220060) | New project
2L Metastatic Breast Cancer
CDK4 inhibitor
sigvotatug vedotin (PF-08046047) | New project
2L Non-Small Cell Lung Cancer (NSCLC) (SGNB6A-002) (Biologic)
Integrin beta-6-directed antibody-drug conjugate
disitamab vedotin (DV) | New project
1L HER2 (=IHC1+) Metastatic Urothelial Cancer (SGNDV-001) (Biologic)
HER2-directed antibody-drug conjugate
TUKYSA (tucatinib) | New project
1L HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
1L HER2+ Maintenance Metastatic Breast Cancer (HER2CLIMB-05)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
2L/3L HER2+ Metastatic Breast Cancer (HER2CLIMB-02)
HER2 tyrosine kinase inhibitor
TUKYSA (tucatinib) | New project
HER2+ Adjuvant Breast Cancer (CompassHER2 RD)
HER2 tyrosine kinase inhibitor
PADCEV (enfortumab vedotin) | New project
Cisplatin-Eligible Muscle-Invasive Bladder Cancer (EV-304) (Biologic)
Nectin-4 directed antibody-drug conjugate
PADCEV (enfortumab vedotin) | New project
Cisplatin-Ineligible/Decline Muscle-Invasive Bladder Cancer (EV-303) (Biologic)
Nectin-4 directed antibody-drug conjugate
vepdegestrant (ARV-471) + IBRANCE | New project
ER+/HER2- Metastatic Breast Cancer (VERITAC 3)
CDK 4,6 kinase inhibitor + ER-targeting PROTAC protein degrader
vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer (VERITAC 2) (FAST TRACK - U.S.)
ER-targeting PROTAC protein degrader
ELREXFIO (elranatamab-bcmm) | New project
Multiple Myeloma Resistant Refractory (MM-32) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (MM-6) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (MM-7) (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Multiple Myeloma Double-Class Exposed (MM-5) (Biologic)
BCMA-CD3 bispecific antibody
BRAFTOVI (encorafenib) + ERBITUX (cetuximab) + chemotherapy | New project
1L BRAF-Mutant Metastatic Colorectal Cancer (BREAKWATER)
BRAF kinase inhibitor
TALZENNA (talazoparib) | New project
Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-Deficient Metastatic Castration Sensitive Prostate Cancer (TALAPRO-3)
PARP inhibitor
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
Non-Muscle-Invasive Bladder Cancer (CREST) (Biologic)
Anti-PD-1
IBRANCE (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA)
CDK 4,6 kinase inhibitor
ADCETRIS (brentuximab vedotin) | New project
Diffuse Large B-Cell Lymphoma (DLBCL) (Biologic)
CD30-directed antibody-drug conjugate